FMP
Fennec Pharmaceuticals Inc.
FENC
NASDAQ
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
9.57 USD
-0.13 (-1.36%)
About
ceo
Mr. Rostislav Raykov
sector
Healthcare
industry
Biotechnology
website
https://www.fennecpharma.com
exchange
NASDAQ
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
CIK
0001211583
ISIN
CA31447P1009
CUSIP
31447P100
Address
68 TW Alexander Drive
Phone
919 636 4530
Country
US
Employee
29
IPO Date
Sep 15, 2017
Key Executives
